Search
Hengrui Medicine Aims to Swiftly Submit Marketing Application for Dual-Target Weight Loss Drug
1 day ago /
Read about 0 minute
Author：小编
The GLP-1/GIP dual receptor agonist, HRS9531 injection, a collaborative effort between Hengrui Medicine and Kailera Therapeutics of the United States, has yielded promising results in Phase III clinical trials for the treatment of obesity and overweight individuals in China. Across all dosage groups, the drug demonstrated superior efficacy compared to placebo. In light of these favorable outcomes, Hengrui Medicine intends to promptly submit a marketing application for HRS9531 as a long-term weight management solution in China.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
